Hard to Treat Diseases (HTDS) 4 Million Dollar Contract To A Major Indian Corporation

SHENZHEN, China, Nov. 3 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS; http://www.htdsmedical.com) Mellow Hope operating subsidiary is in process of finalizing contract details with Hetero Ltd., www.heterodrugs.com one of the largest pharmaceutical manufacturers in India. This contract has been in the works since March 2009, and its finalization promises solid sales boost for Hard to Treat Diseases.

The contract between secures the supply of raw pharmaceutical material for HTDS' Mellow Hope in the range of about 4 million dollars. The contract completion is in final stages, and the shipments are already scheduled. This contract is bound to strengthen present and future sales of the raising pharmaceutical dragon Mellow Hope of Hard to Treat Diseases (HTDS).

In other company news, since September 24, 2009, when Chinese State Food and Drug Administration (SFDA; http://eng.sfda.gov.cn/eng/) granted the H1N1 vaccine licence to Mellow Hope's exclusive business partner Zhejiang Tianyuan Bio-pharmaceutical Co. Ltd., Mellow Hope received inquiries from many potential buyers around the world. At the present, the most promising deals on the horizon include deals with Southeast Asia and Chile. Mellow Hope is the largest exporter of vaccines in China and the H1N1 vaccine licence gives the company a great advantage over the competition. The company expects to make progress announcements on the H1N1 front shortly.

Besides Mellow Hope, Hard to Treat Diseases (HTDS) is also a parent company with operations in Serbia based Slavica Biochem. This company focuses on the enhancement and modification of existing and approved medications as well as on cancer research. This MindUp cancer research has been delivering groundbreaking results on the international level. The company expects to make an announcement with a Canadian based pharmaceutical company on this shortly.

To receive future updates, via email including quarterly newsletters and company updates which may not be newsworthy however important to the reader and followers of the company please sign up today free at www.minamargroup.com/updates

Safe Harbor Statement

Information in this news release may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases Inc. that constitute forward-looking statements for purposes of the Safe Harbor Provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be", "expects", "may affect", "believed", "estimate", "project" and similar words and phrases are intended to identify such forward-looking statements. Hard to Treat Diseases Inc. cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases Inc. is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases Inc.'s control. In addition to those discussed in Hard to Treat Diseases Inc.'s press releases, public filings, and statements by Hard to Treat Diseases Inc.'s management, including, but not limited to, Hard to Treat Diseases Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases Inc.'s ability to raise additional capital to fund future operations, Hard to Treat Diseases Inc.'s ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities, and in identifying contracts which match Hard to Treat Diseases Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

CONTACT: For medical and scientific dialogue inquiry only, please contact medicalinfo@htdsmedical.com; For any corporate matters, please contact www.minamargroup.com/helpdesk; For any retail investor relations matters, please contact www.minamargroup.net/helpdesk, (IR); For (M&A) and Corporate Matters www.minamargroup.com

SOURCE Hard to Treat Diseases